Hyperprolactinemia clinical trials

The registry lists 39 studies for Hyperprolactinemia across more than 10 countries. 4 are recruiting or about to start. 18 of them are mainly about Hyperprolactinemia (how this is decided). Per ClinicalTrials.gov, last updated 2026-04-30.

Get an email when these change. Save the Hyperprolactinemia studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Watch these studies

See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your saved searches, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your saved searches. Stop any time.

Status

Completed: 21
Status unknown: 8
Recruiting: 3
Terminated: 3
Active, not recruiting: 1
Not yet recruiting: 1

Phase

Phase 4: 7
Phase 1: 4
Phase 2: 4
Phase 3: 4

Where

United States: 8
China: 7
Denmark: 3
Switzerland: 3
United Kingdom: 2
Brazil: 2

Who runs them

Pfizer (2) · Massachusetts General Hospital (2) · Changchun GeneScience Pharmaceutical Co., Ltd. (2) · Shanghai Mental Health Center (2) · University Hospitals Coventry and Warwickshire NHS Trust (1) · Cedars-Sinai Medical Center (1) · Fayoum University (1) · The University of Hong Kong (1)

What is being tested here

Drugs under test in Hyperprolactinemia studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Drug	Open	Phase 3	All
Cabergoline	3	2	3
Aripiprazole	0	0	5
KISS1 protein, human	0	0	1
Ropinirole	0	0	1
Metformin	0	0	1
Calcium	0	1	1
Vitamin D	0	1	1
Amantadine	0	0	1
Bromocriptine	0	1	1

Drug classes tested here Dopamine agonists 3 open

Coming up

2phase 3 studies under way

3studies finish main data collection within a year2 of them phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

All 3, phase 3 first

Nov 2026A Phase III Clinical Study of Cabergoline Tablets Compared With Bromocriptine Mesylate Tablets · Phase 3 · Changchun GeneScience Pharmaceutical Co., Ltd.
Aug 2027Safety and Potency of a High Cabergoline Dosage in Microprolactinomas · Phase 3 · University of Sao Paulo General Hospital
Nov 2026Impact of Helicobacter Pylori Infection on Prolactin Levels in Reproductive-Age Women to Determine Whether H. Pylori Infection is Associated with Elevated Prolactin Levels and Assess the Clinical Implications · Assiut University

Who these studies take

Of the 3 Hyperprolactinemia studies recruiting now, 2 (67%) set no upper age limit and 1 (33%) stop at 75 or younger. 0 (0%) take children under 18. 2 (67%) are for women only and 0 (0%) for men only; 0 (0%) take healthy volunteers.

Recruiting studies that take each age, of 3
Age	Women	Men
10	0 (0%)	0 (0%)
18	3 (100%)	1 (33%)
30	3 (100%)	1 (33%)
40	3 (100%)	1 (33%)
50	2 (67%)	1 (33%)
65	2 (67%)	1 (33%)
75	2 (67%)	1 (33%)
85	2 (67%)	1 (33%)

Across all 39 studies, recruiting or not: 67% stop at 75 or younger and 59% at 65; 31% take children; 38% are for women only and 5% for men only; 21% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

Studies

Recruiting first, then most recently updated. Showing 39 of 39. search them.